Jubilant Pharmova has announced that the company, through its subsidiary, has received tentative approval for Pantoprazole Sodium Delayed Release Oral Suspension.
The Noida-based company announced in an exchange filing today (June 26) that after the completion of the pre-approval inspection (PAI) conducted by the United States Food and Drug Administration (USFDA) at the Solid Dosage Manufacturing Facility located at Roorkee, in Uttarakhand, Jubilant Generics Limited, a subsidiary of Jubilant Pharmova, has received a tentative approval from the USFDA for Pantoprazole Sodium Delayed Release Oral Suspension
Jubilant Generics has received approval for Pantoprazole Sodium Delayed-Release Oral Suspension 40 mg per packet.
The tentative approval is subject to the expiry of the patent covering the currently listed Reference Listed Drug (RLD), which is expected to occur in December 2026.
The company said that the final approval is anticipated upon such patent expiry.
When we look at the company’s results in Q4 results, the consolidated net profit for the March quarter stood at ₹119 crore, marking a 23% year-over-year decrease from ₹154 crore during the same period the previous year.
In addition to that, when we look at the profitability, due to increased operational costs and pressure on profitability, the Earnings Before Interest, Taxes, Depreciation, and Amortisation, or EBITDA margin fell dramatically to 14.8% from 17.9%, while EBITDA dipped slightly by 1.6% to ₹339.3 crore from ₹345 crore a year ago.
As far as the company’s stock’s recent performance is concerned, the shares declined on Thursday’s trade, and in the past 6 months of trade, the company’s stock has declined by over 10%. The current stock price stands at ₹964.40 per share.